

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 September 2024 (26.09.2024)



(10) International Publication Number
WO 2024/193541 A1

(51) International Patent Classification:

C07D 417/12 (2006.01) A61K 31/382 (2006.01)
C07D 253/07 (2006.01) A61P 3/04 (2006.01)

(21) International Application Number:

PCT/CN2024/082447

(22) International Filing Date:

19 March 2024 (19.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/082488
20 March 2023 (20.03.2023) CN
PCT/CN2023/101049
19 June 2023 (19.06.2023) CN
PCT/CN2024/079655
01 March 2024 (01.03.2024) CN

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(71) Applicant: **INSILICO MEDICINE IP LIMITED**

[CN/CN]; 26th Floor, Three Exchange Square, 8 Connaught Place Central, Hong Kong (CN).

(72) Inventors: **WU, Jianping**; Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai 201203 (CN). **QIN, Luoheng**; Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai 201203 (CN). **DING, Xiaoyu**; Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai 201203 (CN). **REN, Feng**; Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai 201203 (CN). **LI, Chaopeng**; Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai 201203 (CN).

(74) Agent: **AFD CHINA INTELLECTUAL PROPERTY**

LAW OFFICE; Tower B, 21st Fl. Suite 2108, 38 Xueqing Road, Haidian District, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF

(57) Abstract: Described herein are NLRP3 inflammasome inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with NLRP3 inflammasome pathway.

WO 2024/193541 A1